Insulet Corporation (NASDAQ:PODD – Get Free Report) has been given a consensus rating of “Hold” by the twenty-six brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $186.68.
Several equities analysts recently weighed in on the stock. BTIG Research lowered shares of Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. Leerink Partners lowered shares of Insulet from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $247.00 to $145.00 in a report on Thursday, August 6th. Royal Bank Of Canada dropped their target price on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Raymond James Financial reiterated an “outperform” rating and set a $180.00 target price on shares of Insulet in a research report on Thursday, August 6th. Finally, Oppenheimer downgraded Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th.
Get Our Latest Research Report on PODD
Institutional Investors Weigh In On Insulet
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Insulet during the second quarter valued at approximately $1,018,582,000. Arrowstreet Capital Limited Partnership grew its stake in Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. Man Group plc acquired a new position in shares of Insulet during the 2nd quarter worth approximately $78,746,000. Bank of America Corp DE acquired a new position in shares of Insulet during the 2nd quarter worth approximately $64,921,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Insulet during the 2nd quarter worth approximately $60,615,000.
Insulet Stock Performance
Shares of NASDAQ:PODD opened at $149.68 on Friday. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet has a 1-year low of $126.40 and a 1-year high of $354.88. The stock has a market capitalization of $10.38 billion, a P/E ratio of 27.98, a P/E/G ratio of 1.18 and a beta of 1.11. The business has a 50-day moving average price of $140.91 and a two-hundred day moving average price of $179.87.
Insulet (NASDAQ:PODD – Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same quarter last year, the firm earned $1.17 EPS. The company’s revenue for the quarter was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities analysts predict that Insulet will post 6.51 earnings per share for the current year.
About Insulet
Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.
The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.
Featured Articles
- Five stocks we like better than Insulet
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
